A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery ...

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

London: Neurocrine Biosciences said on Thursday it will halt the development of its experimental drug, aimed at improving cognitive function in patients with schizophrenia, after it did not ...

Sept. 26 (UPI) -- The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia, the FDA announced Thursday. EPA must address health concerns about fluoride in water ...

Neurocrine said it will focus its resources on late-stage development of its other schizophrenia and depression drug candidates. Shares of the company were down 2.5% in extended trading.

It’s that time of year when many of those who have Part D prescription drug coverage experience sticker shock. Here is a sample of what’s happening with my clients. Can this be right?

A 9pm watershed on TV junk food advertising will come into force in October 2025, the government has confirmed. This will come alongside a total ban on paid-for online advertising for junk food ...